Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Penumbra, Inc. Common Stock (NY:PEN)

248.37 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Penumbra, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 Next >
3 Profitable Stocks Walking a Fine Line
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
PENUMBRA INC (NYSE:PEN) – A Strong Growth Stock with Technical Breakout Potential
PENUMBRA INC (NYSE:PEN) is a strong growth stock with solid fundamentals and a promising technical setup. The company shows robust revenue growth, financial health, and breakout potential. 
Via Chartmill
Winners And Losers Of Q1: Penumbra (NYSE:PEN) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks
Let’s dig into the relative performance of Penumbra (NYSE:PEN) and its peers as we unravel the now-completed Q1 medical devices & supplies - cardiology, neurology, vascular earnings season. 
Via StockStory
Peering Into Penumbra's Recent Short Interest
Via Benzinga
3 Small-Cap Stocks Skating on Thin Ice
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
What's Driving the Market Sentiment Around Penumbra?
Via Benzinga
Breaking Down Penumbra: 12 Analysts Share Their Views
Via Benzinga
3 Healthcare Stocks Walking a Fine Line
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
PENUMBRA INC (NYSE:PEN) – A Strong Growth Stock with Technical Breakout Potential
PENUMBRA INC (NYSE:PEN) is a strong growth stock with a bullish technical setup, supported by solid revenue and earnings growth. The company's financial health and breakout potential make it an... 
Via Chartmill
1 High-Flying Stock on Our Buy List and 2 to Avoid
Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices,... 
Via StockStory
PEN Q1 Earnings Call: U.S. Thrombectomy Drives Outperformance as International Headwinds Persist
Medical device company Penumbra (NYSE:PEN) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 16.3% year on year to $324.1 million. The company expects the full year’s revenue to be... 
Via StockStory
Topics World Trade
Earnings Scheduled For April 23, 2025
Via Benzinga
Examining the Future: Penumbra's Earnings Outlook
Via Benzinga
3 Mid-Cap Medical Stocks Outperforming the Market
Several mid-cap medical stocks, such as ADMA, PEN, and TMDX, are outperforming in 2025, showing resilience despite broader market weakness. 
Via MarketBeat
Topics Economy
3 Profitable Stocks in the Doghouse
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
Bausch + Lomb (BLCO) Reports Q1: Everything You Need To Know Ahead Of Earnings
Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting earnings tomorrow before market open. Here’s what you need to know. 
Via StockStory
Topics World Trade
GE HealthCare (GEHC) Reports Q1: Everything You Need To Know Ahead Of Earnings
Healthcare technology company GE HealthCare Technologies (NASDAQ:GEHC) will be reporting earnings tomorrow before market hours. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence World Trade
Align Technology Earnings: What To Look For From ALGN
Dental technology company Align Technology (NASDAQ:ALGN) will be reporting results tomorrow after market close. Here’s what you need to know. 
Via StockStory
Topics Economy World Trade
What To Expect From CONMED’s (CNMD) Q1 Earnings
Medical tech company CONMED (NYSE:CNMD) will be reporting earnings tomorrow after market close. Here’s what you need to know. 
Via StockStory
Topics World Trade
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst
Penumbra Q1 earnings beat estimates with strong sales and thrombectomy growth; analysts raise targets as company reaffirms 2025 guidance. 
Via Benzinga
Topics Earnings
Penumbra’s (NYSE:PEN) Q1 Sales Beat Estimates, Stock Soars
Medical device company Penumbra (NYSE:PEN) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 16.3% year on year to $324.1 million. The company expects the full year’s... 
Via StockStory
Topics Earnings
What To Expect From Penumbra’s (PEN) Q1 Earnings
Medical device company Penumbra (NYSE:PEN) will be reporting results tomorrow after the bell. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Reflecting On Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks’ Q4 Earnings: Merit Medical Systems (NASDAQ:MMSI)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Merit Medical Systems... 
Via StockStory
Unpacking Q4 Earnings: Artivion (NYSE:AORT) In The Context Of Other Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including Artivion (NYSE:AORT) and... 
Via StockStory
Is Penumbra Gaining or Losing Market Support?
Via Benzinga
3 Reasons PEN is Risky and 1 Stock to Buy Instead
In a sliding market, Penumbra has defied the odds, trading up to $255.82 per share. Its 29.5% gain since October 2024 has outpaced the S&P 500’s 13.6% drop. This was partly due to its solid quarterly... 
Via StockStory
Topics Stocks Supply Chain
Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q4 Earnings: ICU Medical (NASDAQ:ICUI) Best of the Bunch
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the medical devices & supplies - cardiology, neurology, vascular stocks, including ICU Medical (NASDAQ:ICUI) and its peers. 
Via StockStory
Peering Into Penumbra's Recent Short Interest
Via Benzinga
What Analysts Are Saying About Penumbra Stock
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.